Skip to content

To study the effect of tarpan with viddhakarma in simple myopia

A Randomized Comparative Clinical Trial to evaluate an add on effect of Viddhakarma with Goghrita Tarpan in management of Simple Myopia. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/091062
Enrollment
68
Registered
2025-07-17
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

PDEAS CARC , Nigadi, Pune
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. The patient within age group of 10 to 35 years irrespective of their gender, socio-economic status and religion having symptoms of Myopia 2. Details Subject clinically diagnosed as Myopia (Refractive error in between Spherical-0.50 to -03.00 Cylindrical upto -1.00 D)

Exclusion criteria

Exclusion criteria: 1. Subject with any other ocular pathology e.g. cataract, corneal opacity, glaucoma, iridocyclitis, Retinal detachment, Macular scar etc. 2. Any previous eye surgery. 3. K/C/O-Any major systemic disease like Hypertension, Diabetes etc. 4. One Eyed Patient 5. K/C/O any bleeding disorders and patient who is taking Anticoagulants.

Design outcomes

Primary

MeasureTime frame
To evaluate the add on effect of Viddhakarma with Goghrita Tarpan on Blurring of Vision in Simple Myopia within duration of 30 days.Timepoint: 30 days.

Secondary

MeasureTime frame
To evaluate the add on effect of Viddhakarma with Goghrita Tarpan on symptoms other than Blurring of Vision in Simple Myopia within duration of 30 days. To observe and compare adverse effects if any.Timepoint: 30 days

Countries

India

Contacts

Public ContactDr VAISHNAVI NANDAKUMAR KUSARE

PDEAs college of ayurved and research centre

drvirkarchandana@gmail.com9822199107

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026